BLASUBCUTANEOUSINJECTABLEPriority Review
Approved
Jun 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
ILARIS (canakinumab) by Novartis is anti-human il-1β antibody of the igg1/κ isotype. Approved for the following autoinflammatory periodic fever syndromes: cryopyrin-associated periodic syndromes (caps) ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (caps), older, hyperimmunoglobulin d (hyper-igd) syndrome (hids)/mevalonate kinase deficiency (mkd) in adult and 4 more indications. First approved in 2009.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILARIS (canakinumab) is a human monoclonal antibody that selectively binds and neutralizes IL-1β, a key driver of inflammation in autoinflammatory and auto-inflammatory diseases. It is indicated for rare periodic fever syndromes including CAPS, HIDS/MKD, FMF, Still's Disease, and SJIA in patients as young as 2 years. The drug blocks IL-1β activity by preventing its interaction with IL-1 receptors, reducing excessive inflammasome-driven cytokine release.
$39MPart D
LOE ApproachingStable
As LOE approaches, the brand is in transition mode with stable but modest spending (~$39M Part D), suggesting a smaller focused team managing a niche therapeutic area rather than major commercial expansion.
Mechanism of Action
anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutralizes its activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra). CAPS refer to rare genetic syndromes generally caused by mutations in the…
Worked on ILARIS at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.